Another trial aimed to treat patients with r/r aggressive B cell NHL with anti-CD19 CAR T cells of a defined composition (JCAR014) in addition to the PD-L1 antibody durvalumab prior to or after CAR T cell administration [83]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.